Abstract
Poorly controlled diabetes mellitus can result in serious complications. Gene therapy is increasingly being considered as an alternative approach to treat diabetes, because of its ability to induce physiological insulin secretion and it allows patients to escape insulin injections. The properties of gut K and L-cells, including glucose sensitivity, the ability to process insulin and a regulated secretion pathway support their use as surrogate β-cells. Previous in vitro studies have provided sufficient evidence supporting the use of these cells for gene therapy studies. Therefore, we examined the ability of K and L-cells to produce insulin in diabetic mice. Chitosan nanoparticles were used to transfer the insulin gene into intestinal cells via oral administration. The efficiency of chitosan as a gene vehicle was investigated through the use of reporter gene. Insulin mRNA and protein expression levels were measured by RT-PCR and ELISA, respectively. Blood glucose testing revealed that this treatment reduced glucose levels in diabetic mice. The decrease in blood glucose level in the first week of treatment was greater in mice with K-cell specific insulin expression compared with mice with L-cellspecific insulin expression. These results indicate that inducing insulin secretion in K-cells conferred a quicker response to gene therapy.
Keywords: Chitosan nanoparticles, diabetes gene therapy, in vivo, K cells and L-cells.
Current Gene Therapy
Title:Insulin Secreted From Genetically Engineered Intestinal Cells Reduces Blood Glucose Levels in Diabetic Mice
Volume: 13 Issue: 4
Author(s): Mina Rasouli, Zeenathul N. Allaudin, Abdul R. Omar and Zalinah Ahmad
Affiliation:
Keywords: Chitosan nanoparticles, diabetes gene therapy, in vivo, K cells and L-cells.
Abstract: Poorly controlled diabetes mellitus can result in serious complications. Gene therapy is increasingly being considered as an alternative approach to treat diabetes, because of its ability to induce physiological insulin secretion and it allows patients to escape insulin injections. The properties of gut K and L-cells, including glucose sensitivity, the ability to process insulin and a regulated secretion pathway support their use as surrogate β-cells. Previous in vitro studies have provided sufficient evidence supporting the use of these cells for gene therapy studies. Therefore, we examined the ability of K and L-cells to produce insulin in diabetic mice. Chitosan nanoparticles were used to transfer the insulin gene into intestinal cells via oral administration. The efficiency of chitosan as a gene vehicle was investigated through the use of reporter gene. Insulin mRNA and protein expression levels were measured by RT-PCR and ELISA, respectively. Blood glucose testing revealed that this treatment reduced glucose levels in diabetic mice. The decrease in blood glucose level in the first week of treatment was greater in mice with K-cell specific insulin expression compared with mice with L-cellspecific insulin expression. These results indicate that inducing insulin secretion in K-cells conferred a quicker response to gene therapy.
Export Options
About this article
Cite this article as:
Rasouli Mina, Allaudin N. Zeenathul, Omar R. Abdul and Ahmad Zalinah, Insulin Secreted From Genetically Engineered Intestinal Cells Reduces Blood Glucose Levels in Diabetic Mice, Current Gene Therapy 2013; 13 (4) . https://dx.doi.org/10.2174/15665232113139990002
DOI https://dx.doi.org/10.2174/15665232113139990002 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Molecular Basis for the Pharmacological Activity of Anthocyans
Current Medicinal Chemistry Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Vitamin A and Diabesity: New Insight for Drug Discovery
Mini-Reviews in Medicinal Chemistry The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets α-Amylase Inhibition: Some Practical Considerations
Current Enzyme Inhibition Electron Spin Resonance as a Powerful Tool for Studying Antioxidants and Radicals
Current Medicinal Chemistry Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Approach to the Patient with Subclinical Cushing’s Syndrome
Current Pharmaceutical Design Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Glyoxal Induced Transition of Transferrin to Aggregates: Spectroscopic, Microscopic and Molecular Docking Insight
Current Pharmaceutical Biotechnology Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study
Current Vascular Pharmacology Factors which Influence the Levels of ST-2, Galectin-3 and MMP-9 in Acute Coronary Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Genetic Analysis of Aldose Reductase in Diabetic Complications
Current Medicinal Chemistry From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) The Immunoregulatory Activity of Mesenchymal Stem Cells: ‘State of Art’ and ‘Future Avenues’
Current Medicinal Chemistry